Total sample size 500 patients
Cost per patient per month $5,000
Planned trial duration 36 months
Enrollment through to primary readout
Enrollment period 18 months
Expected time saved
Expected marginal costs saved
Patients spared Fewer patients exposed to ineffective or unnecessary treatment
Revenue acceleration At ~$500K/day cost-of-delay (Getz 2024)
Timeline comparison
Without BRAKES
Enrollment → Follow-up → Unblind
With BRAKES
Continuous monitoring → Early decision

See what BRAKES would do for your trial

Send us your draft protocol and we'll run a full simulation,
custom-configured to your endpoints, population, and design.